Pharming Agrees To Sell Its Rare Pediatric Disease Priority Review Voucher (PRV) To Novartis Pharma
Portfolio Pulse from Benzinga Newsdesk
Pharming has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis Pharma for a one-time payment of approximately $21.1 million.

June 01, 2023 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis acquires Rare Pediatric Disease PRV from Pharming for $21.1 million, potentially speeding up the approval process for a future drug.
Novartis' acquisition of the PRV from Pharming allows them to potentially expedite the approval process for a future drug targeting a rare pediatric disease. This could lead to faster revenue generation and a competitive advantage in the market, positively impacting Novartis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Pharming sells its Rare Pediatric Disease PRV to Novartis for $21.1 million, providing an immediate cash influx.
Pharming's sale of the PRV to Novartis for $21.1 million provides an immediate cash influx, which can be used to fund research, development, or other strategic initiatives. This could positively impact Pharming's stock price in the short term as investors may view the cash influx as a positive development for the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100